Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia
Article first published online: 22 AUG 2008
© 2008 The Authors. Journal Compilation © 2008 Blackwell Publishing Ltd
British Journal of Haematology
Volume 143, Issue 3, pages 446–450, November 2008
How to Cite
Martin, F. M., Prchal, J., Nieva, J., Saven, A., Andrey, J., Bethel, K., Barton, J. C., Aripally, G., Bottomley, S. S. and Friedman, J. S. (2008), Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia. British Journal of Haematology, 143: 446–450. doi: 10.1111/j.1365-2141.2008.07358.x
- Issue published online: 14 OCT 2008
- Article first published online: 22 AUG 2008
- sideroblastic anaemia;
- iron overload;
- oxidative stress;
- myelodysplastic syndromes
The sideroblastic anaemias (SAs) are a heterogeneous group of inherited (rare) and acquired (relatively common) disorders of erythroid development characterized by iron accumulation within the mitochondria of developing erythroid cells, i.e. ringed sideroblasts (RS). Mutations in a few genes cause types of hereditary SA – including the gene that encodes the haem biosynthetic enzyme 5-aminolevulinate synthase (Cotter et al, 1994), a putative mitochondrial transporter ATP binding cassette b7 (Allikmets et al, 1999) an RNA modifying enzyme, pseudouridine synthase (Bykhovskaya et al, 2004), and a mitochondrial localized protein involved in iron-sulphur cluster biogenesis, glutaredoxin 5 (Camaschella et al, 2007). A large deletion of mitochondrial DNA in Pearson marrow pancreas syndrome causes SA in the context of a multi-system mitochondrial disorder (Rotig et al, 1990). Acquired SA is most commonly seen in myelodysplastic syndromes (MDS), where standard karyotypic analyses have not defined cytogenetic abnormalities that predict the presence of ringed sideroblasts. The significance of mitochondrial DNA mutations in the pathogenesis of SA and MDS remains controversial, with conflicting data as to whether mutation frequency is increased in marrow cells from patients with this group of disorders (Gattermann, 2000; Reddy et al, 2002; Shin et al, 2003), and little direct evidence to link specific mutations with disease (Wulfert et al, 2008). Herein, we describe purification of sideroblasts from human marrow samples employing a simple, magnetic column-based method that was initially developed using a mouse model system (Martin et al, 2005), and present characterization of the purified human cells.
This study included four males and two females, aged 70–85 years, with MDS and RS [three refractory anaemia with ringed sideroblasts (RARS), three multilineage dysplasia or excess blasts]. One RARS patient provided two specimens for this study 10 months apart. One of the MDS patients progressed to acute myeloid leukaemia c. 4 months after a sample was obtained. The seventh patient in this study was a 26-year-old male with X-linked sideroblastic anaemia. All marrow samples were collected with the approval of the Scripps Research Institute human subjects committee. The control marrow specimens lacked RS or evidence of dysplasia. Sideroblasts were purified by adaptation of a simple magnetic column-based method as described previously for purification of murine siderocytes (Martin et al, 2005). Reactive oxygen species (ROS) production, mitochondrial membrane potential (ΔΨm), flow cytometry assays and protein carbonyl determination (oxyblot) were performed as described previously (Martin et al, 2005).
Using a murine model of SA, we have previously demonstrated that the increased intracellular iron characteristic of sideroblasts or siderocytes (enucleated red cells containing iron-loaded mitochondria) can be exploited to obtain a highly purified population of these cells (Martin et al, 2005). Here, we utilized the same method (passage of a cell suspension over a magnetic column in absence of any magnetic bead affinity reagent) for purification of sideroblasts and siderocytes from eight fresh human marrow specimens. 0·29 ± 0·07% vs. 0·08 ± 0·01% of cells were recovered in the column-bound fraction (CBF) relative to starting material (SM) in diseased (n = 8) versus normal (n = 2) whole marrows, respectively. This represents a 3·62-fold greater proportion of magnet+ cells in diseased than in normal samples (Fig 1A). Cell counts included both nucleated cells and erythrocytes in the starting marrow specimens and purified samples.
Magnetic purification of bone marrow suspensions showed a significant enrichment in glycophorin A (GPA)+ and transferrin receptor (CD71)+ iron-overloaded erythroblasts, i.e. sideroblasts (35·07 ± 6·06% of gated cells in CBF vs. 2·27 ± 0·67 and 2·40 ± 1·35% of gated cells in SM and column flow-through (FT), respectively; n = 8; ***P < 0·0001; not shown). Morphology by light microscopy showed that >90% of purified cells were erythroid (erythroblasts to siderocytes) (Fig 1B). Perl’s iron stain demonstrated significant iron accumulation within cells in the magnet-purified fraction – including nucleated RS and siderocytes.
Purified sideroblasts showed a significantly increased mitochondrial membrane potential, ΔΨm, with geometric mean fluorescence intensity (GeoMFI) of 57·05 ± 11·79 relative to SM and FT fractions (5·60 ± 0·87 and 5·54 ± 0·91 GeoMFI, respectively; n = 8; ***P < 0·0001; Fig 2B). These results are similar to those observed when purifying murine sideroblasts/siderocytes in a mouse model of SA secondary to loss of the intramitochondrial antioxidant protein superoxide dismutase 2 (Martin et al, 2005). Elevation of the mitochondrial membrane potential implies an increase in the H+ gradient within the mitochondria, and may reflect a defect in the distal portions of the electron transport chain or a defect in mitochondrial ATP synthesis.
ROS sensitive dyes dihydroethidium (DHE – sensitive to superoxide) and 5,6 chloromethyl 2′,7′ dichlorodihydro-fluorescein diacetate (CM-H2DCFDA – a fluorescein derivative sensitive to peroxide and mixed ROS) were used to measure real-time peroxide and superoxide production in unfractionated marrow, magnet purified and flow through fractions. Most cells in the magnet-purified fraction (CBF) produced ROS, whereas few cells from the SM and FT fractions showed significant dye oxidation (71·27 ± 5·05% of gated cells vs. 1·26 ± 0·22 and 0·89 ± 0·16% of gated cells, respectively; n = 8; ***P < 0·0001; Fig 2A). These results were consistent with comparisons of magnet purified siderocytes from the murine model system (Martin et al, 2005).
Sideroblasts purified from three patients (CBF fractions) showed a significant increase in the amount and complexity of protein oxidative modification, measured as carbonyls (Fig 2C), when compared with an equivalent amount of protein from starting material, or from cells that passed through the magnetic column. This is similar to the enrichment for oxidized proteins observed when purifying sideroblasts/siderocytes from murine marrow or peripheral blood (Martin et al, 2005). This association between excess iron and protein oxidation raises the possibility that redox active iron is a source of protein-damaging ROS via Fenton chemistry in developing erythrocytes.
We have demonstrated a simple and effective method for the enrichment of sideroblasts/siderocytes from marrow specimens of patients with SA or with myelodysplasia with ringed sideroblasts. These cells, purified on a magnet to take advantage of their high iron content, show evidence of increased oxidant production, altered mitochondrial function and oxidative damage to protein. We anticipate that this purified cell population will be useful for additional analyses to delineate other molecular and biochemical lesions characteristic of acquired SA.
F.M. Martin and J.S. Friedman designed the experiments. J. Prchal, J. Nieva, A. Saven, J. Andrei, G. Aripally, S. Bottomley, J. C. Barton and K. Bethel provided the biospecimens and comments on the manuscript. F.M. Martin performed the experiments. F.M. Martin and J.S. Friedman analyzed and interpreted the data and wrote the manuscript.
We thank Dr. Mathieu Marella and Pr. Takao Yagi, TSRI, for assistance and use of their microscope. This work was supported by grants RO1 DK062473 and R21 DK075763 from the National Institutes of Health awarded to J.S.F. and The Stein endowment fund. This is TSRI MS #19210.
- 1999) Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Human Molecular Genetics, 8, 743–749. , , , , & (
- 2004) Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). American Journal of Human Genetics, 74, 1303–1308. , , , & (
- 2007) The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood, 110, 1353–1358. , , , , , , & (
- 1994) X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley. Blood, 84, 3915–3924. , & (
- 2000) From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leukemia Research, 24, 141–151. (
- 2005) A method for rapid mouse siderocyte enrichment. Experimental Hematology, 33, 1493–1499. , , & (
- 2002) Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. British Journal of Haematology, 116, 564–575. , , , , , , , , , , , , , & (
- 1990) Pearson’s marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. Journal of Clinical Investigation, 86, 1601–1608. , , , , , , , , , & (
- 2003) Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood, 101, 3118–3125. , , & (
- 2008) Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Experimental Hematology, 36, 577–586. , , , , , , & (